| Date | Time | Source | Announcement |
|---|---|---|---|
| 06 Mar 2007 | 07:00 AM | Preliminary Results | |
| 28 Feb 2007 | 11:15 AM | Total Voting Rights | |
| 27 Feb 2007 | 11:12 AM | Holding(s) in Company | |
| 27 Feb 2007 | 07:00 AM | Notice of FY2006 Results | |
| 22 Feb 2007 | 09:36 AM | Holding(s) in Company | |
| 20 Feb 2007 | 12:45 PM | Holding(s) in Company | |
| 14 Feb 2007 | 11:04 AM | Holding(s) in Company | |
| 09 Feb 2007 | 10:55 AM | Holding(s) in Company | |
| 07 Feb 2007 | 05:49 PM | Holding(s) in Company | |
| 01 Feb 2007 | 03:18 PM | Result of EGM | |
| 31 Jan 2007 | 06:04 PM | Total Voting Rights | |
| 24 Jan 2007 | 03:39 PM | Holding(s) in Company | |
| 24 Jan 2007 | 07:00 AM | Transgenic Milestone | |
| 16 Jan 2007 | 07:01 AM | Publication of Results | |
| 10 Jan 2007 | 07:00 AM | Phase III Trial of Trovax | |
| 04 Jan 2007 | 04:48 PM | Total Voting Rights-Amendment | |
| 02 Jan 2007 | 03:47 PM | Total Voting Rights-Amendment | |
| 22 Dec 2006 | 11:55 AM | Total Voting Rights | |
| 21 Dec 2006 | 07:00 AM | GSK Lentivector Licence | |
| 19 Dec 2006 | 05:51 PM | Holding(s) in Company | |
| 19 Dec 2006 | 07:00 AM | Licensing Agreement | |
| 08 Dec 2006 | 04:55 PM | Holding(s) in Company | |
| 08 Dec 2006 | 07:00 AM | Positive Opinion on Trovax | |
| 05 Dec 2006 | 07:00 AM | Holding(s) in Company | |
| 21 Nov 2006 | 09:31 AM | Blocklisting Interim Review | |
| 13 Nov 2006 | 07:00 AM | Prosavin preclinical data | |
| 09 Nov 2006 | 07:00 AM | Phase II Results - Trovax | |
| 07 Nov 2006 | 07:00 AM | Phase III Trial in Trovax | |
| 06 Oct 2006 | 07:00 AM | Presentation at Conference | |
| 02 Oct 2006 | 07:00 AM | Gene Therapy for Blindness | |
| 25 Sep 2006 | 02:32 PM | Holding(s) in Company | |
| 20 Sep 2006 | 10:08 AM | Holding(s) in Company | |
| 07 Sep 2006 | 10:54 AM | Interest in Share Options | |
| 05 Sep 2006 | 07:01 AM | SWOG in phase 2 Trovax trial | |
| 05 Sep 2006 | 07:00 AM | Interim Results | |
| 21 Aug 2006 | 07:00 AM | Trovax at Cancer Conference | |
| 03 Aug 2006 | 04:00 PM | Holding(s) in Company | |
| 02 Aug 2006 | 07:00 AM | Notice of Interim Results | |
| 31 Jul 2006 | 07:00 AM | Trovax Update & Clarification | |
| 18 Jul 2006 | 04:09 PM | Holding(s) in Company | |
| 06 Jul 2006 | 04:31 PM | Holding(s) in Company | |
| 05 Jul 2006 | 04:54 PM | Director/PDMR Shareholding | |
| 26 Jun 2006 | 11:43 AM | Holding(s) in Company | |
| 26 Jun 2006 | 07:00 AM | Prosavin Patent | |
| 21 Jun 2006 | 07:00 AM | Piper Jaffray Health Care | |
| 14 Jun 2006 | 07:00 AM | SUIT AGAINST OPEN BIOSYSTEMS | |
| 12 Jun 2006 | 04:00 PM | Holding(s) in Company | |
| 07 Jun 2006 | 07:00 AM | Phase II results - TROVAX | |
| 23 May 2006 | 07:00 AM | Phase II Trial Trovax | |
| 22 May 2006 | 04:30 PM | Holding(s) in Company |
Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.
Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.
Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.